Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419744
Status:
COMPLETED
Last Update Posted:
2010-09-16
First Post:
2007-01-05
Brief Title:
A Comparison of SYMBICORT pMDI With Formoterol Turbuhaler in Subjects With COPD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase IIIB 12-Month Double-blind Double-dummyRandomised Parallel-group Multicentre Exacerbation Study of SYMBICORT pMDI 16045 μg x 2 Actuations Twice-daily and 8045 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 45 μg x 2 Inhalations Twice-daily in COPD Subjects
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if SYMBICORT delivered via a pressurized metered-dose inhaler referred to as a pMDI is effective in preventing COPD exacerbations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None